Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Koji Ando, Al Ozonoff, Shin-Yin Lee, Michael Voisine, Julian-Taylor Parker, Ryota Nakanishi, Sho Nishimura, Jing Yang, Zhao Grace, Ben Tran, Thomas J Diefenbach, Yoshihiko Maehara, Hiroshi Yasui, Tomoyuki Irino, Ravi Salgia, Masanori Terashima, Peter Gibbs, Ramesh K Ramanathan, Eiji Oki, Masaki Mori Show all
Clinical Colorectal Cancer | Elsevier BV | Published : 2020
PURPOSE: The camptothecin (CPT) analogs topotecan and irinotecan specifically target topoisomerase I (topoI) and are used to treat colorectal, gastric, and pancreatic cancer. Response rate for this class of drug varies from 10% to 30%, and there is no predictive biomarker for patient stratification by response. On the basis of our understanding of CPT drug resistance mechanisms, we developed an immunohistochemistry-based predictive test, P-topoI-Dx, to stratify the patient population into those who did and did not experience a response. PATIENTS AND METHODS: The retrospective validation studies included a training set (n = 79) and a validation cohort (n = 27) of gastric cancer (GC) patients,..View full abstract